ImageneBio, Inc.
IMAHealthcareNASDAQBiotechnology · Last scanned Sep 9, 2026
Scan Results
Daily timeframeImageneBio, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for patients with immunological, autoimmune and inflammatory diseases. The $57.4M market capitalization puts IMA squarely in micro-cap range for its industry. Its lead product candidate includes IMG-007, a non-depleting anti-OX40 monoclonal antibody that binds to OX40 receptor on activated T cells to block receptor binding to OX40 ligand which is in Phase 1b/2a clinical trial.
Market Cap
$57.4M
Beta
—
P/E (TTM)
—
P/E (Fwd)
-1.17
EPS (TTM)
$-4.73
EPS (Fwd)
$-4.31
ROE
-82.7%
ROA
-43.1%
Cash
$136.2M
Total Debt
$1.9M
Free CF
-$23.2M
52W Change
-45.6%
Annual Financials
Cash vs Debt
Where IMA stands vs its 150-day and 200-day moving averages
As of the September 3, 2026 close, IMA finished 15.21% below its 150-day moving average ($5.85) and 18.29% below its 200-day moving average ($6.07). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is IMA overbought or oversold?
At the September 3, 2026 close, IMA's RSI(14) was 16.8, in oversold territory (below 30). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
With $136.2M in cash and $1.9M in debt, IMA maintains more liquidity than leverage. This favorable balance sheet position can be an asset when capital markets become less accommodating. The company is burning cash, with free cash flow at -$23.2M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. Return on equity stands at -82.7%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Revenue has pulled back from $8.0M (2023) to $800K (2025), a 90% decline worth watching.
The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. No single metric tells the full story. Reviewing IMA's risk profile alongside its fundamentals and technical indicators provides a more complete picture.